about
Airflow obstruction: is it asthma or is it COPD?Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized MedicinePharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activityThe Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils.Optimizing drug delivery in COPD: The role of inhaler devices.LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment.An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network.HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis.Dual bronchodilation and exacerbations of COPD.A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD.Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects?Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.Olodaterol + tiotropium bromide for the treatment of COPD.Interaction between corticosteroids and muscarinic antagonists in human airways.Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.Acute COPD exacerbation: 3 T MRI evaluation of pulmonary regional perfusion--preliminary experience.Iron laden macrophages in idiopathic pulmonary fibrosis: the telltale of occult alveolar hemorrhage?The prevalence of asthma and COPD in Italy: a practice-based studyCD71- Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease
P50
Q28067052-5B94E274-7433-49FB-984C-F0815C4AFBF5Q33715841-8B50275B-6DB3-4DAE-97D7-00072ACFBBAEQ37001907-4DAEC4E6-7C34-4B84-B03C-F43A49BA8EC5Q37144486-1B57D449-1A7B-4413-B1B1-48FC34F3C8C9Q37378323-BA88C685-5B6F-494E-AFB9-E795016BF973Q38913539-E30C0AE4-48FD-4F31-8B6A-D73B18AF8332Q39092695-118E23D3-961A-40A5-B2E8-36BFE8ED5E59Q40652776-F2BCE331-80FA-4674-B045-3A45CF1A2081Q41693388-8A2A0D7C-AA21-40B8-B4D8-1F3F384F43FAQ42384700-5DFA4BBD-463A-4B25-92C6-4C245819516BQ44377046-2EECEC48-6FB6-4D96-87D0-74EFD420578AQ46349328-0009FE1E-A4AF-4392-A88E-4D3A5646C7ADQ47951337-B9981F23-C858-4218-9D86-6678033D328BQ47966344-DEF6302E-C79D-488F-BFD0-D244A8FFDA1AQ48015797-098B9611-D308-4CE9-8B57-2516E9A266ECQ51278820-F9627F19-5FB4-4F68-8DCE-53B2582BEAFDQ51545895-84C9BA5C-E827-41B9-AD19-C72EB6D70AB9Q51566209-7D3CF7D0-EF5B-4E57-9C6C-F11913E5DFC8Q51601380-AC5E3E71-5C67-47F7-BAE2-1E7C7CA0F3C2Q51726866-E64A7851-ECDE-4FE1-9842-D015C31D3D7FQ53076838-4A21C2C1-AE37-48A7-8F0F-AEF14E7A3FE3Q85203632-33F9F129-F593-46F3-9225-FA879EE7B477Q92199372-21A86DCD-23AF-41C2-8B39-182C6B0293FB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ermanno Puxeddu
@ast
Ermanno Puxeddu
@en
Ermanno Puxeddu
@es
Ermanno Puxeddu
@nl
type
label
Ermanno Puxeddu
@ast
Ermanno Puxeddu
@en
Ermanno Puxeddu
@es
Ermanno Puxeddu
@nl
prefLabel
Ermanno Puxeddu
@ast
Ermanno Puxeddu
@en
Ermanno Puxeddu
@es
Ermanno Puxeddu
@nl
P106
P1153
36892829500
P31
P496
0000-0002-5486-7764